BRAF and melanoma: In another CRISPRa screen for the responses of melanoma cells to the BRAF inhibitor vemurafenib, Joung et al. [143] transduced a 10,504 intergenic lncRNA targeting TSSs sgRNAs into A375 cells and found 11 novel lncRNAs that mediate resistance to vemurafenib and further characterized that transcriptional activation of EMICERI activates the expression of four neighboring protein-coding genes, being any of them sufficient to confer BRAF inhibitor resistance.